HER2-positive breast cancer: Predicting pCR from clinicopathologic variables and genomic testing

Making immune check point inhibitors for lung cancer cost-effective in LMICs

ASCO 2025: Latest in EGFR positive NSCLC

Perioperative durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers

Nivolumab/ipilimumab followed by BRAF/MEK inhibitors preferred sequence for BRAF-positive advanced melanoma

BCG combined with mitomycin offers improved adjuvant treatment regimen for high-risk NMIBC

CtDNA useful biomarker for muscle-invasive bladder cancer patients who received perioperative durvalumab

Sasanlimab BCG combo improves outcomes in high-risk NMIBC

ELCC 2025: Latest in EGFR positive NSCLC

Treatment with BAY 2927088 led to durable responses in patients previously treated HER2-mutant NSCLC

TAR-200 plus cetrelimab show encouraging outcomes for MIBC patients ineligible for standard cisplatin-based chemotherapy

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients